NEW YORK (GenomeWeb) – Agilent Technologies said this week that it has mad an adjustment to its second quarter 2014 GAAP net income. The firm said that it has lowered that figure to $139 million, or $.41 per share, from a previously reported $150 million, or $.45 per share. Agilent said the change was the result of an out-of-period adjustment for tax expense. It added that its Q2 2014 non-GAAP net income was unchanged at $244 million, or $.72 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.